HEALTHCARE ASSOCIATED INFECTION PREVENTION
RESEARCHER PROFILE
Professor Philip Russo (Filmed June 2024)
Professor of Nursing
Director of Research, Nursing & Midwifery, Monash University &
Director of Nursing Research, Cabrini Health, Melbourne, Australia
Professor Russo is Director of Research, Nursing and Midwifery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia and Director of Nursing Research, Cabrini Health.
Professor Russo is an internationally regarded expert in healthcare associated infection prevention, and led the recently completed the Australian National Healthcare Associated Infection Point Prevalence Survey, the first in Australia for 34 years. He is also Past President of the Australasian College for Infection Prevention and Control (ACIPC), the peak body for Infection Prevention and Control professionals in the Australasian region.
Aside from his role at ACIPC, other leadership and engagement activities include; former Deputy Chair of the Infection Control Expert Group (COVID-19), a member of the National COVID-19 Clinical Evidence Taskforce Steering Committee, the National Health and Medical Research Council Infection Control Guidelines Advisory Committee, and the Healthcare Associated Infection Advisory Committee for the Australian Commission on Safety and Quality in Health Care.
Professor Russo is the recipient of a National Health and Medical Research Early Career Fellowship and has attracted research funding from government, industry, philanthropic and academic sources. He has presented at both national and international conferences, authored over 100 peer reviewed articles and several book chapters.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Liver cancer & patient-derived tumour organoids
Dr Benjamin Dwyer is a translational cancer researcher driven by a clear purpose: to ensure discoveries made in the laboratory genuinely improve outcomes for patients.
Based at Curtin University, he established and now leads the organoid platform within the Liver Cancer Collaborative and directs the WA Organoid Innovation Hub, working at the intersection of biology, medicine and biotechnology to accelerate new treatments for liver cancer.
-
Dental care improvements using informatics and artificial intelligence
a member of the Scientific Advisory Committee for Dentroid, a startup in Australia aiming to revolutionise dentistry with laser technology. He has gained extensive experience in various roles at research-intensive institutions across three different continents.
